Overview
- NICE’s recommendation covers people aged 26 and over with relapsed or refractory B‑cell acute lymphoblastic leukaemia.
- Patients will receive two intravenous doses ten days apart at selected CAR‑T centres, with initial capacity expected to treat around 50 people a year in England.
- Trials reported 77% remission, with roughly half of those remaining free of detectable cancer at about three and a half years, and an average 15.6‑month survival gain.
- The therapy showed lower toxicity than earlier CAR‑T options, with a design intended to limit severe immune reactions and enable potential outpatient use.
- Aucatzyl was invented at UCL and will be manufactured by Autolus in Stevenage, following MHRA conditional authorisation granted in April 2025.